Skip to main content
Premium Trial:

Request an Annual Quote

Beckman's Q2 Sales Miss Target as Profits Fall 20 Percent

NEW YORK (GenomeWeb News) — Beckman Coulter today reported a slight decrease in second-quarter sales accompanied by a 19-percent drop in net income.
 
Total receipts for the three months ended June 30 declined to $616.3 million, from $618.8 in the same period last year. Beckman had initially forecast revenues to be between $620 million and $645 million, and the company blamed the lower-than-expected revenues on lagging sales in the Asian market.
 
Research and development costs rose 50 percent to $75 million from $50 million year over year.
 
Net income for the quarter dropped 19 percent to $44.6 million from $55.2 million in the prior-year period.
 
As of June 30, Beckman Coulter had $59.4 million in cash and cash equivalents.
 
Beckman CEO Scott Garrett said that  the "revenues in the Far East were disappointing due to a combination of factors” including slower-than-expected transition to a direct sales model in China and the fact that “hospitals are delaying purchases due to an expanding Chinese government review of overall hospital buying practices.”
 
Garrett said that Beckman expects to be “back on track with [its] double-digit growth trend” by the beginning of 2007.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.